Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Mallinckrodt
Baxter
Express Scripts
Merck

Last Updated: May 27, 2022

FORTESTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Fortesta patents expire, and what generic alternatives are available?

Fortesta is a drug marketed by Endo Pharms and is included in one NDA.

The generic ingredient in FORTESTA is testosterone. There are sixty-nine drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Fortesta

A generic version of FORTESTA was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Try it Free

Drug patent expirations by year for FORTESTA
Drug Prices for FORTESTA

See drug prices for FORTESTA

Drug Sales Revenue Trends for FORTESTA

See drug sales revenues for FORTESTA

Recent Clinical Trials for FORTESTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Endo PharmaceuticalsPhase 4
Johns Hopkins UniversityPhase 4
Endo PharmaceuticalsPhase 3

See all FORTESTA clinical trials

Paragraph IV (Patent) Challenges for FORTESTA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FORTESTA Gel testosterone 10 mg/actuation 021463 1 2012-08-14

US Patents and Regulatory Information for FORTESTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FORTESTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 See Plans and Pricing See Plans and Pricing
Endo Pharms FORTESTA testosterone GEL, METERED;TRANSDERMAL 021463-001 Dec 29, 2010 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Dow
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.